2025-126D - Laserfiche WebLink

Home Browse Search

Docusign Envelope ID: 921 F7A24-D5CE-4BCC-9F3C-5E7844661266 (a) Standard Clinical Programs. RIGHTWAY's standard clinical programs may include the following offerings. (i) Concurrent Drug Utilization Review. Participating Pharmacies will be provided with information concerning drug interaction, safety edits, and generic substitution and therapeutic intervention programs. Providers are individually responsible for acting or not acting upon information generated and transmitted and for performing Services in each jurisdiction consistent with the scope of their licenses. These drug utilization review services are necessarily limited by the amount, type, and accuracy of Eligible Person information made available to RIGHTWAY. (ii) Retrospective Drug Utilization Review. RIGHTWAY will retrospectively review previously approved Claims for potential fraud or abuse, and clinical appropriateness. RIGHTWAY will analyze Eligible Persons' drug profiles and review one or more specific therapeutic categories or issues. Automatic algorithms will be employed to identify Eligible Persons receiving the profiling and targeted drug therapy. RIGHTWAY also will contact Practitioners and Participating Pharmacies as needed to discuss therapeutic issues and to offer suggestions for alternative therapy. (iii) Treatment Alternatives. Client agrees that consistent with the F PAA Privacy Rule and applicable Law, RIGHTWAY may contact Eligible Persons to provide refill reminders or information about treatment alternatives, including, but not limited to, Brand and Generic Covered Products, or other health-related benefits and services that may be of interest to such Eligible Persons. In connection with these services, RIGHTWAY also may provide Participating Pharmacies and Practitioners information, electronic messaging, and communications about such alternatives and services. Client further agrees that Participating Pharmacies and Practitioners may contact Eligible Persons regarding refill reminders or information about treatment alternatives, provided that such action is not inconsistent with applicable medical standards of care or any limitation imposed by applicable Law. (iv) Prior Authorizations. RIGHTWAY will provide Client with Prior Authorization/step therapy services. (v) Quantity Limits. RIGHTWAY will provide Client with quantity limit services. (vi) Formulary Management. RIGHTWAY shall provide a recommended drug Formulary to Client and Client hereby adopts, as part of the Plan design and as Client's formulary, such Formulary (as amended from time to time). Client agrees to implement, administer, and cooperate with RIGHTWAY and to facilitate Eligible Persons' utilization of the Formulary. Notwithstanding anything to the contrary in the Agreement, Client hereby authorizes RIGHTWAY to implement Prior Authorizations, step therapy edits, and quantity limits under the Formulary. RIGHTWAY may communicate with Eligible Persons, Participating Pharmacies, and Practitioners regarding the Formulary. Such communications may include, but are not limited to (a) pre -implementation letters to Eligible Persons targeting prescription drugs that are no longer covered by the Formulary or that may require a generic product to be tried prior to the brand product, (b) post -implementation letters sent to impacted Eligible Persons alerting them of any Formulary changes, and (c) notification letters to Practitioners identifying the drugs available on the Formulary. (vii) Formulary Support Programs. RIGHTWAY will offer Client Formulary support programs intended to assist in the transition of Client's Eligible Persons from their 32 This document is CONFIDENTIAL AND PROPRIETARY to RIGHTWAY Healthcare, Inc. and may not be reproduced, transmitted, published, or disclosed to others without the prior written authorization of RIGHTWAY Healthcare, Inc.